Inventor
JAMES E. BRADNER
Inventor
US
Overview
Patents· 7 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
A61Kprimary
A61KPreparations for medical, dental or toiletry purposes24%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations24%
C07DHeterocyclic compounds24%
G01NInvestigating or analysing materials by determining their chemical or physical properties10%
C07CAcyclic or carbocyclic compounds3%
C07KPeptides3%
C12NMicroorganisms or enzymes3%
C12YEnzymes3%
Y02ATechnologies for adaptation to climate change3%
PatentTitleYear
11,999,802Compositions and methods for selective protein degradation202411,666,580Mechanism of resistance to bet bromodomain inhibitors202311,617,750Reverse amide compounds as protein deacetylase inhibitors and methods of use thereof202311,446,309Combination therapy for cancer using bromodomain and extra-terminal (BET) protein inhibitors202211,406,645Acetamide thienotriazolodiazepines and uses thereof202211,306,105Cyano thienotriazolodiazepines and uses thereof202211,236,082EZH2 inhibitors and uses thereof2022Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2022–2023Patents assigned to DANA FARBER CANCER INST INC (5)· patent assignee history
2022–2024Based in US· patent location history
2023Patents assigned to ACETYLON PHARMACEUTICALS INC (1)· patent assignee history
2024Patents assigned to NOVARTIS AG (1)· patent assignee history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| DANA FARBER CANCER INST INC | 5 | 2022–2023 |
| ACETYLON PHARMACEUTICALS INC | 1 | 2023 |
| NOVARTIS AG | 1 | 2024 |
Locations
| Location | Patents | Span |
|---|---|---|
| US | 7 | 2022–2024 |